Tumour‐derived transforming growth factor‐β signalling contributes to fibrosis in patients with cancer cachexia

Cachexia is a paraneoplastic syndrome related with poor prognosis. The tumour micro‐environment contributes to systemic inflammation and increased oxidative stress as well as to fibrosis. The aim of the present study was to characterise the inflammatory circulating factors and tumour micro‐environment profile, as potentially contributing to tumour fibrosis in cachectic cancer patients.

[1]  Y. Shan,et al.  Elevated Serum Interleukin-8 Level Correlates with Cancer-Related Cachexia and Sarcopenia: An Indicator for Pancreatic Cancer Outcomes , 2018, Journal of clinical medicine.

[2]  L. Oyama,et al.  Peritumoural adipose tissue pro‐inflammatory cytokines are associated with tumoural growth factors in cancer cachexia patients , 2018, Journal of cachexia, sarcopenia and muscle.

[3]  Chenwei Wang,et al.  A molecular portrait of epithelial–mesenchymal plasticity in prostate cancer associated with clinical outcome , 2018, Oncogene.

[4]  Qiang Yu,et al.  Hypoxic tumor microenvironment activates GLI2 via HIF-1α and TGF-β2 to promote chemoresistance in colorectal cancer , 2018, Proceedings of the National Academy of Sciences.

[5]  A. Borczuk,et al.  Metastatic cancers promote cachexia through altered zinc homeostasis in skeletal muscle , 2018, Nature Medicine.

[6]  R. Varshney,et al.  Platelet TGF-β1 deficiency decreases liver fibrosis in a mouse model of liver injury. , 2018, Blood advances.

[7]  Camille Stephan-Otto Attolini,et al.  TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis , 2018, Nature.

[8]  G. Thomas,et al.  Quantitative proteomic profiling of primary cancer-associated fibroblasts in oesophageal adenocarcinoma , 2018, British Journal of Cancer.

[9]  J. Carson,et al.  Linking Cancer Cachexia-Induced Anabolic Resistance to Skeletal Muscle Oxidative Metabolism , 2017, Oxidative medicine and cellular longevity.

[10]  C. Vilos,et al.  TGF-β requires the activation of canonical and non-canonical signalling pathways to induce skeletal muscle atrophy , 2017, Biological chemistry.

[11]  S. Anker,et al.  Ethical guidelines for publishing in the journal of cachexia, sarcopenia and muscle: update 2017 , 2017, Journal of cachexia, sarcopenia and muscle.

[12]  Ruchi Bansal,et al.  Drug targeting to myofibroblasts: Implications for fibrosis and cancer , 2017, Advanced drug delivery reviews.

[13]  Yong Zhou,et al.  Tumor induces muscle wasting in mice through releasing extracellular Hsp70 and Hsp90 , 2017, Nature Communications.

[14]  Hui Peng,et al.  An epithelial-to-mesenchymal transition-inducing potential of granulocyte macrophage colony-stimulating factor in colon cancer , 2017, Scientific Reports.

[15]  Dennis K Fix,et al.  Disrupted Skeletal Muscle Mitochondrial Dynamics, Mitophagy, and Biogenesis during Cancer Cachexia: A Role for Inflammation , 2017, Oxidative medicine and cellular longevity.

[16]  P. Singh,et al.  Abstract LB-267: Metabolic alterations in tumors cause cachexia in pancreatic cancer , 2017 .

[17]  Ye Zeng,et al.  Epithelial-mesenchymal transition in cancer: Role of the IL-8/IL-8R axis. , 2017, Oncology letters.

[18]  A. Gemma,et al.  XPLN is modulated by HDAC inhibitors and negatively regulates SPARC expression by targeting mTORC2 in human lung fibroblasts. , 2017, Pulmonary pharmacology & therapeutics.

[19]  C. Eaves,et al.  Modeling the process of human tumorigenesis , 2017, Nature Communications.

[20]  B. Jenkins,et al.  Blockade of the IL-6 trans-signalling/STAT3 axis suppresses cachexia in Kras-induced lung adenocarcinoma , 2017, Oncogene.

[21]  B. Kong,et al.  Cancer cachexia-induced muscle atrophy: evidence for alterations in microRNAs important for muscle size. , 2017, Physiological genomics.

[22]  J. Marie,et al.  Transforming growth factor β: a master regulator of the gut microbiota and immune cell interactions , 2017, Clinical & translational immunology.

[23]  J. Otoch,et al.  Adipose tissue fibrosis in human cancer cachexia: the role of TGFβ pathway , 2017, BMC Cancer.

[24]  S. Di Marco,et al.  STAT3 promotes IFNγ/TNFα‐induced muscle wasting in an NF‐κB‐dependent and IL‐6‐independent manner , 2017, EMBO molecular medicine.

[25]  F. Celi,et al.  The role of adipose tissue in cancer-associated cachexia , 2017, Experimental biology and medicine.

[26]  Hetal J. Patel,et al.  TNF‐&agr; and cancer cachexia: Molecular insights and clinical implications , 2017, Life sciences.

[27]  G. Pazour,et al.  Ror2 signaling regulates Golgi structure and transport through IFT20 for tumor invasiveness , 2017, Scientific Reports.

[28]  S. Lakka,et al.  SPARC overexpression alters microRNA expression profiles involved in tumor progression , 2017, Genes & cancer.

[29]  R. Xu,et al.  The TGF-β/Smad4 Signaling Pathway in Pancreatic Carcinogenesis and Its Clinical Significance , 2017, Journal of clinical medicine.

[30]  J. Kanwar,et al.  Redox Control of Antioxidant and Antihepatotoxic Activities of Cassia surattensis Seed Extract against Paracetamol Intoxication in Mice: In Vitro and In Vivo Studies of Herbal Green Antioxidant , 2016, Oxidative medicine and cellular longevity.

[31]  V. Butiurca,et al.  Systematic review of the old and new concepts in the epithelial-mesenchymal transition of colorectal cancer. , 2016, World journal of gastroenterology.

[32]  A. Borczuk,et al.  An analysis of the relationship between metastases and cachexia in lung cancer patients , 2016, Cancer medicine.

[33]  F. Wang,et al.  TGF-β1 contributes to CD8+ Treg induction through p38 MAPK signaling in ovarian cancer microenvironment , 2016, Oncotarget.

[34]  M. Swarbrick,et al.  Lipolytic and thermogenic depletion of adipose tissue in cancer cachexia. , 2016, Seminars in cell & developmental biology.

[35]  A. Moustakas,et al.  In vitro and ex vivo vanadium antitumor activity in (TGF-β)-induced EMT. Synergistic activity with carboplatin and correlation with tumor metastasis in cancer patients. , 2016, The international journal of biochemistry & cell biology.

[36]  E. Wagner,et al.  Mechanisms of metabolic dysfunction in cancer-associated cachexia , 2016, Genes & development.

[37]  B. Xing,et al.  CD34 Over-Expression is Associated With Gliomas’ Higher WHO Grade , 2016, Medicine.

[38]  Jun Shi,et al.  Interleukin-8: A potent promoter of angiogenesis in gastric cancer. , 2016, Oncology letters.

[39]  P. Porporato.  Understanding cachexia as a cancer metabolism syndrome , 2016, Oncogenesis.

[40]  Ke Chen,et al.  Reactive Oxygen Species and Targeted Therapy for Pancreatic Cancer , 2016, Oxidative medicine and cellular longevity.

[41]  G. Trinchieri,et al.  Systemic Inflammation in Cachexia – Is Tumor Cytokine Expression Profile the Culprit? , 2015, Front. Immunol..

[42]  A. Laviano,et al.  Inflammation in Cachexia , 2015, Mediators of inflammation.

[43]  E. Nice,et al.  Transforming growth factor-β, MAPK and Wnt signaling interactions in colorectal cancer , 2015 .

[44]  B. Hinz.  The extracellular matrix and transforming growth factor-β1: Tale of a strained relationship. , 2015, Matrix biology : journal of the International Society for Matrix Biology.

[45]  L. Bretillon,et al.  Cellular and Molecular Connections between Autophagy and Inflammation , 2015, Mediators of inflammation.

[46]  J. Otoch,et al.  Cachexia‐associated adipose tissue morphological rearrangement in gastrointestinal cancer patients , 2015, Journal of cachexia, sarcopenia and muscle.

[47]  G. Püschel,et al.  NF-κBp65 and Expression of Its Pro-Inflammatory Target Genes Are Upregulated in the Subcutaneous Adipose Tissue of Cachectic Cancer Patients , 2015, Nutrients.

[48]  V. Prod’homme,et al.  Tumour-derived SPARC drives vascular permeability and extravasation through endothelial VCAM1 signalling to promote metastasis , 2015, Nature Communications.

[49]  C. Ruppert,et al.  Compromised peroxisomes in idiopathic pulmonary fibrosis, a vicious cycle inducing a higher fibrotic response via TGF-β signaling , 2015, Proceedings of the National Academy of Sciences.

[50]  P. Papageorgis.  TGFβ Signaling in Tumor Initiation, Epithelial-to-Mesenchymal Transition, and Metastasis , 2015, Journal of oncology.

[51]  C. Brinckerhoff,et al.  CXCR3 Signaling in BRAFWT Melanoma Increases IL-8 Expression and Tumorigenicity , 2015, PloS one.

[52]  A. van Maanen,et al.  Role of Activin A and myostatin in human cancer cachexia. , 2015, The Journal of clinical endocrinology and metabolism.

[53]  J. Cutz,et al.  Novel function of Oncostatin M as a potent tumour‐promoting agent in lung , 2015, International journal of cancer.

[54]  P. Papageorgis,et al.  Role of TGFβ in regulation of the tumor microenvironment and drug delivery (Review) , 2015, International journal of oncology.

[55]  O. Tsave,et al.  Mechanisms and Αpplications of Ιnterleukins in Cancer Immunotherapy , 2015, International journal of molecular sciences.

[56]  D. Bolignano,et al.  Emerging markers of cachexia predict survival in cancer patients , 2014, BMC Cancer.

[57]  M. Muscaritoli,et al.  Ghrelin: from discovery to cancer cachexia therapy , 2014, Current opinion in clinical nutrition and metabolic care.

[58]  A. Bergeron,et al.  IL-8 secretion in primary cultures of prostate cells is associated with prostate cancer aggressiveness , 2014, Research and reports in urology.

[59]  S. Koul,et al.  Role of p38 MAP Kinase Signal Transduction in Solid Tumors. , 2013, Genes & cancer.

[60]  Ariana Peck,et al.  Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers , 2013, Nature.

[61]  A. Klein-Szanto,et al.  Periostin cooperates with mutant p53 to mediate invasion through the induction of STAT1 signaling in the esophageal tumor microenvironment , 2013, Oncogenesis.

[62]  F. Rossi Fanelli,et al.  Comparison of the performance of four different tools in diagnosing disease-associated anorexia and their relationship with nutritional, functional and clinical outcome measures in hospitalized patients. , 2013, Clinical nutrition.

[63]  R. Ordoñez,et al.  Inhibition of VEGF expression through blockade of Hif1α and STAT3 signalling mediates the anti-angiogenic effect of melatonin in HepG2 liver cancer cells , 2013, British Journal of Cancer.

[64]  K. Khazaie,et al.  Tumor STAT1 Transcription Factor Activity Enhances Breast Tumor Growth and Immune Suppression Mediated by Myeloid-derived Suppressor Cells* , 2013, The Journal of Biological Chemistry.

[65]  Y. Hasegawa,et al.  Emerging evidence of epithelial‐to‐mesenchymal transition in lung carcinogenesis , 2012, Respirology.

[66]  Duane H. Hamilton,et al.  Influence of IL-8 on the epithelial-mesenchymal transition and the tumor microenvironment. , 2012, Future oncology.

[67]  J. Werner,et al.  Stellenwert der Autopsie bei Patienten mit Kopf-Halstumoren , 2012, Laryngo Rhino Otologie.

[68]  J. Rosa,et al.  Exercise Training Decreases Adipose Tissue Inflammation in Cachectic Rats , 2012, Hormone and Metabolic Research.

[69]  J. Reynolds,et al.  Cancer Cachexia: Mechanisms and Clinical Implications , 2011, Gastroenterology research and practice.

[70]  C. Rancourt,et al.  Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients , 2011, BMC Cancer.

[71]  R. Knight,et al.  STAT1 interacts directly with cyclin D1/Cdk4 and mediates cell cycle arrest , 2010, Cell cycle.

[72]  P. Ponikowski,et al.  Cachexia: a new definition. , 2008, Clinical nutrition.

[73]  B. Gornicka,et al.  Impaired glucose metabolism in colorectal cancer , 2006, Scandinavian journal of gastroenterology.

[74]  E Helene Sage,et al.  Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. , 2003, Cancer research.

[75]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[76]  D. Osoba,et al.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.

[77]  Mathias Müller,et al.  The good and the bad faces of STAT1 in solid tumours. , 2017, Cytokine.

[78]  X. Ren,et al.  IL-8, a novel messenger to cross-link inflammation and tumor EMT via autocrine and paracrine pathways (Review). , 2016, International journal of oncology.

[79]  B. Bobek-Billewicz,et al.  Markers of angiogenesis ( CD 31 , CD 34 , rCBV ) and their prognostic value in low-grade gliomas , 2014 .

[80]  B. Bobek-Billewicz,et al.  Markers of angiogenesis (CD31, CD34, rCBV) and their prognostic value in low-grade gliomas. , 2013, Neurologia i neurochirurgia polska.

[81]  F. Rossi Fanelli,et al.  Neuroinflammation: a contributing factor to the pathogenesis of cancer cachexia. , 2012, Critical reviews in oncogenesis.

[82]  S. B. Peres,et al.  Adipose tissue inflammation and cancer cachexia: possible role of nuclear transcription factors. , 2012, Cytokine.

[83]  J. Werner,et al.  [Significance of autopsy in patients with head and neck cancer]. , 2012, Laryngo- rhino- otologie.